Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-134

Folks, what we need to remember is this -

It is extremely hard, as an investigator, to recruit patients of that calibre for a P3 trial.

We're currently at 150+ patients out of 300.

That's 150+ very sick patients on ventilators who have agreed to take a coin toss on receiving the treatment for the greater good.

Currently, the mortality rate for C-19 patients on ventilators are ~80%. That's 8 out of 10 patients dying while ventilated.

I can't even begin to imagine what that decision must have felt like. To know that you may or may not get the treatment, but in case I don't, and the treatment gets approved, I am on top of the list to get it.

So, in the pursuit for share price appreciation, let's not forget what a noble decision these patients must have made to enrol in our trial.

One can only hope and pray that those who ended up taking the placebo will be able to survive to see Rem-L get approved and then receive and experience the treatment first hand.